Immunome Inc.
varegacestat
desmoid tumors
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on varegacestat for desmoid tumors is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“plans to submit a New Drug Application to the U.S. Food and Drug Administration for varegacestat in the second quarter of 2026.”